Literature DB >> 8197474

Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat.

Christine M Ambrose1, Mabel P Duyao1, Glenn Barnes1, Gillian P Bates2, Carol S Lin1, Jayalakshmi Srinidhi1, Sarah Baxendale2, Holger Hummerich2, Hans Lehrach2, Michael Altherr3, John Wasmuth3, Alan Buckler1, Deanna Church1, David Housman4, Mary Berks5, Gos Micklem5, Richard Durbin5, Alan Dodge6, Andrew Read6, James Gusella1,7, Marcy E MacDonald1.   

Abstract

Huntington's disease, a neurodegenerative disorder characterized by loss of striatal neurons, is caused by an expanded, unstable trinucleotide repeat in a novel 4p16.3 gene. To lay the foundation for exploring the pathogenic mechanism in HD, we have determined the structure of the disease gene and examined its expression. The HD locus spans 180 kb and consists of 67 exons ranging in size from 48 bp to 341 bp with an average of 138 bp. Scanning of the HD transcript failed to reveal any additional sequence alterations characteristic of HD chromosomes. A codon loss polymorphism in linkage disequilibrium with the disorder revealed that both normal and HD alleles are represented in the mRNA population in HD heterozygotes, indicating that the defect does not eliminate transcription. The gene is ubiquitously expressed as two alternatively polyadenylated forms displaying different relative abundance in various fetal and adult tissues, suggesting the operation of interacting factors in determining specificity of cell loss. The HD gene was disrupted in a female carrying a balanced translocation with a breakpoint between exons 40 and 41. The absence of any abnormal phenotype in this individual argues against simple inactivation of the gene as the mechanism by which the expanded trinucleotide repeat causes HD. Taken together, these observations suggest that the dominant HD mutation either confers a new property on the mRNA or, more likely, alters an interaction at the protein level.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8197474     DOI: 10.1007/BF02257483

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN: 0740-7750


  64 in total

Review 1.  Transgenic models of Huntington's disease.

Authors:  K Sathasivam; C Hobbs; L Mangiarini; A Mahal; M Turmaine; P Doherty; S W Davies; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.

Authors:  E Martín-Aparicio; A Yamamoto; F Hernández; R Hen; J Avila; J J Lucas
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 3.  Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts?

Authors:  D C Rubinsztein; A Wyttenbach; J Rankin
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

Review 4.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

5.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

6.  Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system.

Authors:  P Kahlem; C Terré; H Green; P Djian
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 7.  The genetic defect causing Huntington's disease: repeated in other contexts?

Authors:  J F Gusella; F Persichetti; M E MacDonald
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

Review 8.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

9.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

10.  Neuronal induction of the immunoproteasome in Huntington's disease.

Authors:  Miguel Díaz-Hernández; Félix Hernández; Ester Martín-Aparicio; Pilar Gómez-Ramos; María A Morán; José G Castaño; Isidro Ferrer; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.